Interpace Biosciences, Inc.
IDXG
$1.14
-$0.03-2.56%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 125.94% | -37.92% | 340.60% | -77.08% | 432.57% |
| Total Depreciation and Amortization | 11.64% | 0.53% | 17.50% | -13.98% | -47.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -100.00% |
| Total Other Non-Cash Items | -49.60% | 6,957.14% | -94.26% | -71.89% | -0.46% |
| Change in Net Operating Assets | -1,516.99% | 117.94% | -5.57% | 46.91% | -265.98% |
| Cash from Operations | -44.05% | 50.71% | 2,520.69% | -105.09% | 3.17% |
| Capital Expenditure | 75.29% | -164.97% | -603.57% | 80.28% | 6.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Investing | 75.29% | -164.97% | -603.57% | 80.28% | -140.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 25.00% | -233.33% | -- | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -13.80% | 25.00% | -233.33% | 76.30% | -68.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -793.62% | 111.85% | -15.60% | 55.28% | -3,163.83% |